Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 1

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 2(3)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02449239Phase 3Completed

Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG

Role: lead

NCT00481936Phase 1Terminated

Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin

Role: lead

NCT00462488Phase 2Completed

Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

Role: lead

NCT00272181Phase 2Terminated

Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

Role: lead

NCT00412776Phase 2Terminated

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

Role: lead

All 5 trials loaded